PCSA Processa Pharmaceuticals, Inc. Stock Quote

PCSA [NASD]

Index	-	P/E	-	EPS (ttm)	-1.91	Insider Own	4.20%	Shs Outstand	13.37M	Perf Week	-18.91%
Market Cap	143.70M	Forward P/E	-	EPS next Y	-0.53	Insider Trans	-41.31%	Shs Float	6.17M	Perf Month	-27.13%
Income	-19.00M	PEG	-	EPS next Q	-0.10	Inst Own	12.20%	Short Float	0.88%	Perf Quarter	26.02%
Sales	-	P/S	-	EPS this Y	-263.00%	Inst Trans	-	Short Ratio	0.64	Perf Half Y	81.47%
Book/sh	1.72	P/B	5.01	EPS next Y	-26.20%	ROA	-138.90%	Target Price	-	Perf Year	-64.82%
Cash/sh	0.92	P/C	9.33	EPS next 5Y	-	ROE	-180.10%	52W Range	3.40 - 14.24	Perf YTD	30.71%
Dividend	-	P/FCF	-	EPS past 5Y	-5.70%	ROI	-	52W High	-39.96%	Beta	0.16
Dividend %	-	Quick Ratio	13.30	Sales past 5Y	-	Gross Margin	-	52W Low	151.47%	ATR	0.71
Employees	14	Current Ratio	13.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	28.86	Volatility	6.37% 6.71%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-361.70%	Profit Margin	-	Rel Volume	0.16	Prev Close	8.62
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 25 AMC	Payout	-	Avg Volume	84.85K	Price	8.55
Recom	2.00	SMA20	-21.39%	SMA50	-19.50%	SMA200	6.22%	Volume	6,605	Change	-0.81%

Mar-25-21 04:06PM	Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update GlobeNewswire
Mar-22-21 09:15AM	Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET GlobeNewswire
Mar-17-21 09:15AM	Processa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica GlobeNewswire
Mar-02-21 09:15AM	Processa Pharmaceuticals Announces Closing of a $10.2 Million Private Placement GlobeNewswire
Feb-22-21 08:30AM	Encode Ideas, L.P. Announces the Initiation of Research Coverage on Processa Pharmaceuticals, Inc. Newsfile +6.80%
Feb-19-21 05:16AM	Do Institutions Own Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares? Simply Wall St.
Feb-17-21 08:00AM	Processa Pharmaceuticals Announces $10.2 Million Strategic Financing GlobeNewswire +33.17%
Jan-11-21 10:50AM	Processa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference GlobeNewswire
Nov-16-20 12:48PM	Processa Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire +5.39%
Nov-12-20 05:02PM	Processa Pharmaceuticals Announces Third Quarter 2020 Results, Provides Corporate Update GlobeNewswire
Nov-05-20 09:15AM	Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors GlobeNewswire
Nov-03-20 09:20AM	Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on Nov. 12 at 5:30 p.m. ET GlobeNewswire
Oct-13-20 09:30AM	Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer GlobeNewswire
Oct-07-20 09:25AM	Patrick Lin Is The Co-Founder of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) And They Just Picked Up 8.5% More Shares Simply Wall St. +7.84%
Oct-06-20 04:05PM	Processa Pharmaceuticals Closes $19.2 Million Public Offering GlobeNewswire
Oct-02-20 06:00AM	Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market GlobeNewswire -35.25%
Aug-27-20 09:30AM	PROCESSA PHARMACEUTICALS ENTERED INTO A CONTINGENT PRECEDENT IN-LICENSING AGREEMENT WITH ELION ONCOLOGY FOR THE DEVELOPMENT OF ENILURACIL (PCS6422) FOR THE TREATMENT OF ADVANCED GASTROINTESTINAL TUMORS GlobeNewswire +10.00%
Aug-20-20 09:30AM	PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH YUHAN CORPORATION FOR THE DEVELOPMENT OF YH12852 IN FUNCTIONAL GASTROINTESTINAL DISORDERS GlobeNewswire
Jun-01-20 09:30AM	PROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS ENTERED INTO AN AGREEMENT WITH APOSENSE, LTD TO LICENSE IN THE NEXT GENERATION IRINOTECAN DRUG GlobeNewswire
Mar-30-20 04:00PM	PROCESSA PHARMACEUTICALS TO MOVE FORWARD WITH A PCS499 PHASE 3 TRIAL AFTER A SUCCESSFUL FDA MEETING GlobeNewswire
Mar-17-20 09:30AM	PROCESSA PHARMACEUTICALS ANNOUNCES RESULTS FROM THE PHASE 2 STUDY IN NECROBIOSIS LIPOIDICA GlobeNewswire
Mar-05-20 09:30AM	PROCESSA PHARMACEUTICALS ANNOUNCES FORMATION OF ITS MEDICAL AND SCIENTIFIC ADVISORY BOARD GlobeNewswire
Feb-25-20 09:30AM	PROCESSA PHARMACEUTICALS PROVIDES SHAREHOLDER UPDATE GlobeNewswire
Feb-13-20 09:30AM	PROCESSA PHARMACEUTICALS APPOINTS GERALDINE PANNU AS AN INDEPENDENT DIRECTOR TO THE BOARD OF DIRECTORS GlobeNewswire
Dec-20-19 04:10PM	PROCESSA PHARMACEUTICALS ANNOUNCES 1 FOR 7 REVERSE STOCK SPLIT OF ITS COMMON STOCK GlobeNewswire

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Yorke Justin W	Director	Apr 14	Sale	9.42	9,700	91,374	248,272	Apr 15 04:33 PM
Yorke Justin W	Director	Apr 13	Sale	9.86	6,500	64,090	257,972	Apr 15 04:33 PM
BESSER JAMES E		Apr 08	Sale	10.76	400,000	4,304,000	648,300	Apr 08 06:05 PM
BESSER JAMES E		Apr 07	Sale	10.67	16,000	170,720	1,048,300	Apr 08 06:05 PM
BESSER JAMES E		Apr 06	Sale	10.91	31,771	346,622	1,064,300	Apr 08 06:05 PM
BESSER JAMES E	10% Owner	Feb 22	Sale	11.56	20,929	241,939	1,096,071	Feb 22 08:13 PM
BESSER JAMES E	10% Owner	Feb 19	Sale	11.20	3,000	33,600	1,117,000	Feb 22 08:13 PM
BESSER JAMES E	10% Owner	Feb 18	Sale	11.35	5,000	56,750	1,120,000	Feb 22 08:13 PM
BESSER JAMES E	10% Owner	Oct 02	Buy	4.04	30,000	121,200	405,000	Oct 13 06:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience